Experimentally induced autoimmune encephalomyelitis (EAE) in mice provides an animal model that shares many features with human demyelinating diseases such as multiple sclerosis (MS). To what extent the cerebral cortex is affected by the process of demyelination and how the corollary response of the oligodendrocyte lineage is explicated are still not completely known aspects of EAE. By performing a detailed in situ analysis of expression of myelin and oligodendrocyte markers we have identified areas of subpial demyelination in the cerebral cortex of animals with conventionally induced EAE conditions. On EAE-affected cerebral cortices, the distribution and relative abundance of cells of the oligodendrocyte lineage were assessed and compared with control mouse brains. The analysis demonstrated that A2B5 + glial restricted progenitors (GRPs) and NG2 + /PDGFR-α + oligodendrocyte precursor cells (OPCs) were increased in number during "early" disease, 20 days post MOG immunization, whereas in the "late" disease, 39 days post-immunization, they were strongly diminished, and there was an accompanying reduction in NG2 + /O4 + pre-oligodendrocytes and GST-π mature oligodendrocytes. These results, together with the observed steady-state amount of NG2 − /O4 + pre-myelinating oligodendrocytes, suggested that oligodendroglial precursors attempted to compensate for the progressive loss of myelin, although these cells appeared to fail to complete the last step of their differentiation program. Our findings confirm that this chronic model of EAE reproduces the features of neocortex pathology in progressive MS and suggest that, despite the proliferative response of the oligodendroglial precursors, the failure to accomplish final differentiation may be a key contributing factor to the impaired remyelination that characterizes these demyelinating conditions.
Introduction
Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model characterized by inflammatory demyelination of the central nervous system (CNS), as occurs in the human disease multiple sclerosis (MS). Disease heterogeneity in terms of clinical course and neuropathology is characteristic of MS (Lucchinetti et al., 2000) and is also a feature of EAE. In fact, in the latter, depending upon the species, strain, immunization protocol and dosage of the immunogen, relapsingremitting or chronic models can be reproduced (Berard et al., 2010; Gold et al., 2006) . In patients with progressive MS the brain is globally affected, as a consequence of the persistent and diffuse inflammatory process, showing diffuse demyelination, axonal loss and microglial activation in normal appearing WM as well as in deep and cortical grey matter (GM) (Bø et al., 2003; Bø, 2009; Kidd et al., 1999; Kutzelnigg et al., 2005; Peterson et al., 2001; Rudick and Trapp, 2009 ). Although only a marginal correlation between focal WM lesions and cortical pathology has been described, demyelination within cortical GM areas may contribute to disease progression and also play a role in the emergence of cognitive deficits (Chen et al., 2004; De Stefano et al., 2003; Geurts et al., 2009; Kutzelnigg et al., 2005; Lazeron et al., 2000; Stadelmann et al., 2008) . Conventional EAE mouse models, including MOG-induced EAE, have been most commonly adopted to focus on spinal cord inflammation/demyelination (Gold et al., 2006) , while neocortex demyelination has been primarily described in specifically designed experimental models (Pomeroy et al., 2005; Merkler et al., 2006; Storch et al., 2006) . Data on cortical lesions were reported by Rasmussen et al. (2007) in relapsing-remitting rodent EAE induced by PLP and only very recently, forebrain demyelination has been demonstrated in chronic EAE, induced by MOG in C57BL/6 mice, that mimics primary and secondary progressive MS (Mangiardi et al., 2011) .
Concurrently with destructive events, regenerative processes take place in MS and EAE demyelinated lesions of WM, including attempts by nervous tissue to remyelinate the damaged areas (Albert et al., 2007; Blakemore, 1974; Bunge et al., 1961; Franklin and ffrench-Constant, 2008; Patani et al., 2007; Prineas et al., 1993) . The heterogeneity observed in the degree of remyelination in samples collected from autopsies and biopsies could be related to patients' age and MS clinical subtypes (Frohman et al., 2006; Lassmann et al., 1997; Goldschmidt et al., 2009; Patrikios et al., 2006) . It has been demonstrated that some chronic MS lesions contain immature oligodendrocytes, which can be involved in the phenomenon of remyelination (Chang et al., 2000 (Chang et al., , 2002 Wolswijk, 1998 Wolswijk, , 2002 , but a comprehensive analysis of the sequential maturation stages of oligodendrocyte lineage during chronic evolution of the disease is still lacking.
In the perinatal period of normal brain development, oligodendrocytes arise from precursors that differentiate through a series of stages identified by specific markers: glial restricted progenitors (GRPs) recognized by the phenotype marker A2B5 which corresponds to a specific group of gangliosides (Cameron and Rakic, 1991; Kundu et al., 1983; Liu et al., 2002; Steiner et al., 2007; Strathmann et al., 2007) , oligodendrocyte precursor cells (OPCs) identified by NG2 (nerve-glial antigen 2) chondroitin sulphate proteoglycan and by PDGFR-α (platelet derived growth factor receptor-α), molecules both involved in cell proliferation and migration (He et al., 2009; Heldin and Westermark, 1999; Chekenya et al., 2008; Kucharova and Stallcup, 2010; Makagiansar et al., 2007) , pre-oligodendrocytes also expressing NG2 and identified by the phenotype marker O4, which recognizes specific glycolipids and cholesterol (Bansal et al., 1989; Baumann and Pham-Dihn, 2001; Cai et al., 2006; Guardia Clausi et al., 2010; Probstmeier et al., 1999; Sommer and Schachner, 1981) , myelinating oligodendrocytes that express myelin-associated proteins, MBP and MOG, and specific enzymes, CNPase and GST-π (Baumann and Pham-Dihn, 2001; Quarles, 1997; Tansey and Cammer, 1991) . In the adult CNS, NG2-expressing cells, OPCs/polydendrocytes and pre-oligodendrocytes are still present. Polydendrocytes are morphologically and antigenically indistinguishable from OPCs but in normal conditions they represent a non-proliferating, stable cell population (Butt et al., 2005; Fruttiger et al., 1999; Goldman, 2005; Levine et al., 1993; Nishiyama et al., 1996 Nishiyama et al., , 2009 . Although several studies have described the presence of cells of the oligodendrocyte lineage in EAE demyelinating lesions of the spinal cord, relatively little is known about the situation in the cerebral cortex (Di Bello et al., 1999; Gensert and Goldman, 1997; Keirstead et al., 1998; Papadopoulos et al., 2010; Polito and Reynolds, 2005; Reynolds et al., 2002) . Considering that the origin, identity and degree of maturation of the cells that may play an effective role during the remyelination process remain of primary interest, also in view of observations made on human MS lesions, in this study we have analyzed the presence and distribution of oligodendrocyte lineage cells in the cerebral cortex of MOG-induced chronic EAE. The antigenic phenotype of oligodendroglia precursors and myelinating oligodendrocytes has been revealed by a broad panel of cell-specific markers during "early" and "late" stages of the disease with the aim of defining the mode, extent, and course of the oligodendrocyte response in relation to the neocortex demyelination events.
Materials and methods

EAE induction and clinical evaluation
Procedures involving animals and their care were conducted in conformity with the institutional guidelines in compliance with national (D.L. n. 116, G.U., suppl. 40, Feb. 18, 1992) and international laws and policies (EEC Council Directive 86/609, OJ L 358, 1, Dec.12, 1987 ; Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996) . The protocols for the proposed investigation were reviewed and approved by the Animal Care and Use Committees (IACUC) of the "Mario Negri" Institute for Pharmacological Research. Chronic EAE was induced in C57BL/6 wild type female mice (6-8 weeks of age) obtained from Harlan (Bresso, MI, Italy) and maintained in specific pathogen-free conditions. EAE was induced by subcutaneous immunization with a total of 200 μg of MOG in incomplete Freund's adjuvant (Sigma, St. Louis, MO, USA), supplemented with 8 mg/ml of Mycobacterium tuberculosis (strain H37RA; Difco, Detroit, MI, USA). The mice received 300 ng of pertussin toxin (Sigma) i.v. at the immunization time and 48 h later. Control C57BL/6 female mice received a subcutaneous injection of incomplete Freund's adjuvant without MOG . Weight and clinical score (cs) were recorded daily according to the standard EAE grading scale. The onset of EAE clinical signs was at 13-14 days post-immunization (dpi). On the total immunized mice (n = 16), a first group of mice was sacrificed during "early EAE" (n = 9; cs 1.5 to 3.5) at 20 dpi, while a second group was followed up to 39 dpi, defined as "late EAE" (n = 6; cs 2.0 to 3.0). Individual clinical scores were plotted per day, data were expressed as median ± SEM ( Supplementary Fig. 1 ). For each experimental group, healthy controls (n = 5) were sacrificed at equivalent times.
Histology and Immunohistochemistry
Mice were anesthetized with chloral hydrate (3 μl/g, intraperitoneal injection) and transcardially perfused with 100 ml of fixative (2% paraformaldehyde plus 0.2% glutaraldehyde). After perfusion, each hemisphere was cut into 20-μm thick sagittal sections then immunostained for light microscopy or confocal laser microscopy, except for sections that were stained with toluidine blue for comparative microanatomy analysis. The following primary antibodies were utilized in single and multiple immunolabelings: anti-MBP (Myelin Basic Protein), anti-A2B5, anti-NG2 (nerve-glial antigen 2), anti-NeuN (Neuronal Nuclei), anti-O4, anti-PDGFR-α (platelet derived growth factor receptor-α), anti-CNPase (2′,3′-Cyclic Nucleotide 3′-Phosphodiesterase), anti-MOG (Myelin Oligodendrocyte Glycoprotein, anti-GST-π (glutathione S-transferase isoform-π), anti-GFAP (Glial Fibrillary Acidic Protein), anti-NF (70 kDa Neurofilament), anti-CD45, anti-PCNA (Proliferative Cell Nuclear Antigen). The initial analysis of both cerebral cortex and subcortical white matter myelination levels, in healthy and EAE-affected mice, was carried out by immunoenzymatic methods to reveal the myelin marker MBP. Subsequently, adjacent sections were immunolabeled for laser confocal analysis with a number of markers (Table 1) , according to the protocols described in the Supplementary materials. Sections were examined under a Leica TCS SP5 confocal laser scanning microscope (Leica Microsystems, Mannheim, Germany).
Quantitative assessment
Brains from healthy (n = 5), "early EAE" (20 dpi; n = 5), and "late EAE" (39 dpi; n = 5) mice were utilized for computer-aided morphometric analysis. 
Results
Immunolocalization of cells of the oligodendrocyte lineage in cerebral cortex of healthy mice
The distribution and characteristics of the cells of the oligodendrocyte lineage were evaluated in healthy mice with the aid of specific markers. On sections double immunolabeled for A2B5 and NG2, a number of A2B5 a Primary antibodies combinations in multiple immunolabelings: A2B5 combined with NG2 (revealed by 3, 4, 6 immunoreagents, ir) or NeuN (3, 4, 5 ir); NG2 combined with GFAP (6, 7 ir), O4 (3, 4, 6 ir), CNPase (6, 7 ir), MOG (6, 8 ir), PCNA (6, 7 ir), PDGFR-α (9, 12 ir); MBP combined with MOG and CNPase (9, 10, 11 ir); MBP combined with NF (6, 8 ir); MBP combined with CD45 (9, 12 ir). Supplementary Figs. 4 f-h ). In addition to these general myelin markers, and to better evaluate the amount of mature oligodendrocytes throughout the cortex and WM, single labelings were also carried out with the oligodendrocyte-specific enzyme GST-π, that specifically marks the cell body ( Supplementary Figs. 5 a-c) Figs. 6d-f ).
Immunohistochemical analysis of myelinated fibers in cerebral cortex of EAE mice
Brain sections from EAE-affected mice sacrificed at 20 and 39 dpi, defined as "early" and "late" disease, respectively, were analyzed for the distribution of both MBP and MOG reactivity. In both stages of the disease, MBP and MOG immunoreactivity appeared significantly reduced in cerebral cortex and subcortical WM (Figs. 1a, b; 2a) . In the cerebral cortex of EAE-affected mice, together with the diffuse reduction of MBP, localized areas characterized by a reduced or absent MBP reactivity were also frequently seen in the form of band-like subpial demyelination (Figs. 1a-d ) and rarely as bounded lesions either extending up to layer IV (Fig. 1e) , or to the subcortical WM (Fig. 1f) . MBP reactivity also appeared significantly reduced in the supragranular and granular layers of mice in the "late" stage of the disease (39 dpi) as compared with the "early" stage (20 dpi) (Fig. 2a) . Double stainings with anti-MBP and anti-NF antibodies were also carried out to ascertain whether the observed areas of myelin loss corresponded to primary demyelination, which is characterized by a relative sparing of axons. In EAE-affected cortex, at both 20 and 39 dpi the depletion of MBP was confirmed and NF + "naked" axons were still recognizable (Figs. 1g, h ). According to the results described above, serial sections close to the detected demyelinated cortical areas were stained with the microglia/leukocyte marker CD45. In the cortex, a large population of activated microglia cells, identifiable by a low CD45 expression, was revealed together with spread macrophage-like cells, identified on the basis of a high CD45 expression (Almolda et al., 2009) (Figs. 3a, b) . These CD45 high -reactive cells were frequently associated with demyelinating fibers (Figs. 3c, d ; Supplementary Video 1) and increased during the disease course, while typical inflammatory infiltrates were never seen around cerebral cortex microvessels either at 20 dpi or at 39 dpi (Fig. 3a) . These observations demonstrated that a demyelination process occurs in the cerebral cortex and subcortical WM of the analyzed EAE mice and prompted us to further investigate the distribution of oligodendrocyte lineage cells during the disease course.
Immunolocalization of cells of the oligodendrocyte lineage in EAE cerebral cortex at 20 dpi
Quantitative analysis of double immunolabeled A2B5/NG2 sections from EAE-affected mice demonstrated that the number of A2B5 + /NG2 − GRPs was significantly increased in supragranular and granular layers, deeper subgranular layers and WM (Figs. 2b, 4a, b) , the highest number of GRPs being observed in subpial cortex areas. Although the number of A2B5 + GRPs was increased in EAE-affected mice, the total A2B5 staining of the cortex was not significantly different from the staining obtained in control cortex (Fig. 2a) . This discrepancy could be explained by the observed reduction of the A2B5 reactivity in the EAE neuropil and neuron nuclei (Figs. 4a, b) . As already observed in control brains, a small number of 'transitional' OPCs was also identifiable by reactivity for both A2B5 and NG2 (Fig. 2b) ; p= 0.012; n = 5) ( Fig. 2b; Supplementary Fig. 7) , that also confirmed a steady state in deep cortex layers and WM (3750.87 ± 1261.84 vs 3886.52 ± 1157.92 cells/mm 3 ; p = 0.86; n = 5). Unlike GRPs and OPCs, the NG2 + /O4 + pre-oligodendrocytes did not increase in number (Fig. 2b) but they expressed high levels of NG2 and, especially in supragranular layers, showed a deeply modified morphology characterized by an enlarged, polymorphic cell body bearing numerous dendritic-like processes (Fig. 4d ). In accordance with the previous NG2 labeling results, the area of immunoreactivity for NG2 was also significantly increased in supragranular and granular layers (Fig. 2a) . A slight increase of NG2 − /O4 + pre-myelinating oligodendrocytes was observed in all cortical layers and WM (Figs. 2b, 4c-f ) and was paralleled by the value of O4 immunoreactive cortex areas (Fig. 2a) . To ascertain a possible relation between the increase of NG2 + oligodendroglial precursors and the reduced level of myelination observed in supragranular and granular cortex layers in "early EAE", we morphometrically analyzed NG2, CNPase, MOG, and MBP reactivity. As compared to the peak observed in NG2 immunoreactivity, myelin markers showed a significant reduction (Figs. 2a; 5a-f), paralleled by a non-significant decrease in the number of mature oligodendrocytes identified by 5g, h ). An additional feature of the EAE cerebral cortex was the presence of transitional NG2 + /CNPase + pre-myelinating oligodendrocytes (Figs. 6a-c) , which were never seen in control cortex, as well as of polymorphic NG2 + and O4 + doublet cells (Figs. 6d-f ) that are considered aspects of cell proliferation. To better evaluate the presence of an increased proliferative capacity of the oligodendrocyte precursors during "early EAE", double immunolabelings were carried out with NG2 and the proliferative marker PCNA. The analysis, performed by counting the percentage of NG2 + cells marked by PCNA, revealed an increase of proliferation that, in EAE cerebral cortex, accounted for 6.02 ± 0.91% of the whole NG2 + population vs 3.50 ± 1.27% in control brains (p = 0.0069; n = 5) (Figs. 6g, h ).
Immunolocalization of cells of the oligodendrocyte lineage in EAE cerebral cortex at 39 dpi
Comparison between the observed changes in 20 dpi, "early EAE", and 39 dpi, "late EAE", demonstrated that a severe decrease in the number of precursors of the oligodendrocyte lineage took place in the "late" stage of the disease. The reduction involved A2B5 showed a statistically significant decreased number as compared with those in controls and in "early" disease (Fig. 2b) . In particular, the number of OPCs, that had been demonstrated to increase at 20 dpi, showed a significant reduction in 39 dpi mice, in both supragranular and granular cerebral cortex layers (1884.03 ± 804.96 vs 5944.68 ± 1075.04; p= 0.0001; n = 5) and subgranular layers and WM (1118.48± 397.95 vs 3750.87 ± 1261.84; p = 0.0021; n = 5) (Fig. 2b) . A significant reduction of mature GST-π + oligodendrocytes was also observed as compared to controls, and was paralleled by a further decrease of MOG and MBP immunoreactivity (Figs. 2a, b) . Among the different types of immature and mature oligodendrocytes, only the differentiated NG2 − / O4 + pre-myelinating oligodendrocytes did not appear quantitatively reduced (Fig. 2b) . Overall, these data indicated that in "late EAE" the main observed changes consisted of a progressive process of demyelination together with an arrest of oligodendrocyte precursors proliferation.
Discussion
Neocortical lesions have long been recognized to be present in MS (Brownell and Hughes, 1962; Greenfield and King, 1936) and to be prominent in patients with progressive MS (Bø et al., 2003; Geurts et al., 2009; Kidd et al., 1999) . In the past decade, only few, specifically modeled EAE experiments have demonstrated a cortical involvement similar to that seen in MS in humans (Merkler et al., 2006; Pomeroy et al., 2005; Storch et al., 2006) , while conventional MOG-induced EAE in C57BL/6 mice has been extensively studied and has not previously been documented to display grey matter lesions (Kim et al., 2010; Zamvil and Steinman, 1990) , even if in this model indirect evidence of cerebral cortex disease has been suggested (Tu et al., 2009; Zeis et al., 2008) . Recently, the histopathological bases of inflammation and demyelination in the cerebral cortex and corpus callosum have been described in chronic EAE induced by MOG peptide 35-55 in C57BL/6 mice (Mangiardi et al., 2011) . Interestingly, in this study demyelinating lesions located in different areas of the cerebral cortex, as well as structural and functional alterations, have been demonstrated to mimic cortical and callosal pathologic abnormalities of progressive MS. Our study confirms the presence of cerebral cortex demyelinating lesions in the standard MOG-induced EAE mouse model and extends the analysis to the changes that involve the oligodendrocyte cell lineage. Areas of subpial demyelination were disclosed in the form of band-like diffuse myelin reduction and as bounded areas resembling the general subpial demyelination, type III and type IV lesions described in the cerebral cortex of progressive MS patients (Bø et al., 2003; Geurts et al., 2005; Peterson et al., 2001) . In cortical lesions of progressive MS, signs of remyelination have also been shown (Albert et al., 2007; Patani et al., 2007) , however, the immunomorphological criteria adopted in this study do not allow us to distinguish between partially demyelinated and remyelinating fibers, making it impossible to establish whether new wrapping of demyelinated axons occurs during the phases of the disease under study. As recently demonstrated, new molecular markers of demyelination/remyelination are needed to specifically identify the ongoing processes (Ma et al., 2011) .
Thereafter, we identified and quantitatively evaluated, on the basis of the study carried out on control brains with a broad panel of oligodendrocyte markers, the morphological and quantitative changes that occur in the cells of the oligodendrocyte lineage in EAE-affected brains. In the control cerebral cortex and subcortical WM, virtually all the cells of the oligodendrocyte lineage are identified by their morphology and antigenic phenotype ( Supplementary Fig. 8 ), the prevalent population being OPCs/polydendrocytes. Other numerically considerable precursors were GRPs and pre-oligodendrocytes; the former have previously been revealed in the developing brain and are considered as early progenitors of the oligo-astroglia cell lineage (Liu et al., 2002; Strathmann et al., 2007) . As demonstrated in the developing murine cerebral cortex, the subpial area is an additional niche for oligodendrogenesis (Costa et al., 2007) . At this site, the oligodendrogenesis that takes place in adulthood may be reactivated in EAE conditions and evidence for this reactivation may be afforded by the increment of GRPs.
Based upon the outcome of our phenotypical study, the large population of NG2 + cells includes the classically described OPCs/ polydendrocytes, which also show specific reactivity for PDGFR-α, and encompasses a subset of pre-oligodendrocytes identified by their coincident O4 expression. In "early EAE", NG2 + oligodendroglial cells seem to react to demyelination by pronounced proliferation. The proliferative response of NG2 + cells has been reported in previous studies (Di Bello et al., 1999; Keirstead et al., 1998; Polito and Reynolds, 2005; Reynolds et al., 2002) and has been suggested to be promoted by interactions of NG2 with non-myelinated axons (Kucharova and Stallcup, 2010 ). In our model, the proliferative attitude of NG2 + cells is suggested by the presence of NG2 + doublet cells, deemed to be dividing cells that maintain a differentiated morphology (Ge et al., 2009; Kukley et al., 2008) , and is confirmed by morphometric analysis of proliferating precursors identified by NG2/PCNA markers. In "early EAE", proliferation of NG2 + cells in cerebral cortex increases two-fold in the subpial cortex layers, where a more evident and extended demyelination has also been demonstrated. The emerging data on proliferation and differentiation capacities of OPCs endorse the concept of a fundamental contribution of these cells to CNS plasticity under physiological conditions and during remyelination (Staugaitis and Trapp, 2009; Tripathi et al., 2010; Zawadzka et al., 2010; Zhu et al., 2011) . As compared with other precursors of the glial lineage, OPCs, which are present both during brain development and in adulthood, are extremely plastic and may respond to the neural microenviroment by exerting multiple functions, as well as resuming their proliferative capability (Mangin and Gallo, 2011; Simon et al., 2011; Wigley et al., 2007) . In this view, it is conceivable that during the early phase of MS, proliferation of OPCs may occur as a response to short-lasting demyelination, initiating, together with other mechanisms such as the release of anti-inflammatory cytokines and redistribution of axon channels, a repair process (Chang et al., 2000; Hollifield et al., 2003; Moll et al., 1991 (Keirstead and Blakemore, 1997) . It is known that cultured OPCs undergo a finite number of cell divisions, after which they differentiate into more mature oligodendrocytes, even when proliferative stimuli are provided in excess Raff et al., 1988) . In fact, in the "late" disease, when the process of demyelination becomes more evident, the proliferation potential of precursors seems to become exhausted and an overwhelming loss of the entire oligodendrocyte lineage takes place. The number of oligodendrocyte precursors significantly declines along with that of mature myelinating oligodendrocytes, while premyelinating oligodendrocytes seem to be the only cell type that remains numerically stable. This can be explained by considering that at least a subset of the OPCs present at the "early" stage of the disease may embark upon a differentiation program to generate, in "late EAE", the population of pre-myelinating oligodendrocytes that, however, ; subgranular layers and WM: control 24992.85 ± 874.86 vs EAE 15276.27 ± 8293.68 cell/mm appears to be unable to sustain the decreasing population of mature oligodendrocytes.
Different mechanisms have been suggested to sustain the MS/EAE pathogenesis and outcome, including a reduction of differentiationinducing signals, the presence of local inhibitors of oligodendrocyte differentiation and/or axon-wrapping capacities (Butovsky et al., 2006; Chen et al., 2009; Höftberger et al., 2010; Huang et al., 2011; Jurynczyk et al., 2008; Kremer et al., 2011; Mi et al., 2005) , modified interactions with the dystrophic axons (Chang et al., 2002; John et al., 2002) . In this context, our results confirm that a defect in the differentiation program may specifically intervene in critical steps of oligodendrocyte maturative progression (Kuhlmann et al., 2008) , and pinpoint the maturational block in a late differentiation stage, possibly coinciding with pre-myelinating oligodendrocytes.
Overall, the observations carried out in this chronic EAE model identify a two-phase response of oligodendrocyte precursors, provide an additional phenomenological basis for a better understanding of the pathogenesis of progressive MS, and suggest the proliferative response of OPCs during "early EAE" as a potential for remyelination, as well as offering indications underlining the importance of implementing early therapeutic strategies aimed at impeding the progression to extensive demyelination.
Supplementary materials related to this article can be found online at doi:10.1016/j.nbd.2011.05.021.
